Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Mdm García-Valdés"'
Autor:
R Claramunt García, C Alarcon-Payer, JM Puerta-Puerta, R García-Fumero, A. Jiménez-Morales, Mdm García-Valdés
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance In managing chronic lymphocytic leukaemia (CLL), it is recommended that patients with TP53 deletion/mutation (TP53mut), who have a poor prognosis, are treated with ibrutinib as frontline therapy. Because of severe infectious